Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol, Merck End Pargluva Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb says it will consider pursuing commercialization of muraglitazar independently.

You may also be interested in...



AstraZeneca Discontinues PPAR Candidate Galida

Safety issues have plagued development of the diabetes treatment class.

AstraZeneca Discontinues PPAR Candidate Galida

Safety issues have plagued development of the diabetes treatment class.

Pargluva Development May Be Terminated By Bristol, Merck

Regulatory approval and commercial success of the investigational type 2 diabetes drug will require additional clinical trials that could take up to five years to complete, Bristol says.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel